NCT02571842.

Methods	Parallel RCT
Participants	Setting: single centre Country: Thailand Any kidney transplant recipients between the age of 18 and 70 years of age and able to give informed consent; GFR by 24‐hour CrCl > 30 mL/min/1.73 m2; biopsy‐proven recurrent IgAN with endocapillary proliferation pattern Number: 30 participants planned Mean age ± SD (years): not available Sex (M/F): not available Exclusion criteria: clinical and histologic evidence of IgA combination with other forms of GN; clinical evidence of cirrhosis, chronic active liver disease or known infection with hepatitis B, C or HIV; 24‐hour CrCl < 30 mL/min/1.73 m2 at the time of screening; active systemic infection or history of serious infection within one month of entry; positive pregnancy test or breast feeding at time of study entry; patients receiving > 6 months therapy with oral prednisone > 5 mg/day or glucocorticoid equivalent; live vaccine within 28 days of study enrolment
Interventions	Treatment group 1 Rituximab: 375 mg/m2 on treatment month 1, 2, 3, 4 Treatment group 2 An ACEI and/or ARB will be used to achieve proteinuria reduction and a BP goal of < 130/80 mmHg. Patients not attaining the target BP with an ACEI or ARB alone should be treated with the combination of ACEI + ARB Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6 to 8 weeks to 5 mg/day daily
Outcomes	Remission rate Incidence of all adverse events
Notes	Study completed on December 2016 Email investigators to request update on trial status, but not answer was provided Clinicaltrials.gov identifier: NCT02571842 No study results available

ACEi ‐ angiotensin‐converting enzyme inhibitor; ARB ‐ angiotensin receptor blocker; BP ‐ blood pressure; CPA ‐ cyclophosphamide; CrCl ‐ creatinine clearance; CSA ‐ cyclosporin A; (e)GFR ‐ (estimated) glomerular filtration rate; GN ‐ glomerulonephritis; HIV ‐ human immunodeficiency virus; HSP ‐ Henoch‐Schönlein Purpura; IgAN ‐ IgA nephropathy; IV ‐ intravenous; MMF ‐ mycophenolate mofetil; RCT ‐ randomised controlled study; SLE ‐ systemic lupus erythematosus; UACR ‐ urine albumin creatinine ratio